Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRCT
stocks logo

PRCT

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
75.67M
+41.82%
-0.413
-17.33%
82.34M
+41.07%
-0.357
-10.83%
95.87M
+40.49%
-0.284
-18.73%
Estimates Revision
The market is revising Upward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 9.21%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.53%
In Past 3 Month
Stock Price
Go Up
up Image
+9.21%
In Past 3 Month
10 Analyst Rating
up Image0
Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 78.50 USD with a low forecast of 70.00 USD and a high forecast of 90.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 58.350
sliders
Low
70.00
Averages
78.50
High
90.00
up Image0
Current: 58.350
sliders
Low
70.00
Averages
78.50
High
90.00
Morgan Stanley
Overweight
downgrade
$71 -> $68
2025-07-15
New
Reason
Morgan Stanley
Price Target
$71 -> $68
2025-07-15
New
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Procept BioRobotics to $68 from $71 and keeps an Overweight rating on the shares.The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Stephens
Mason Carrico
Overweight
initiated
$70
2025-07-09
Reason
Stephens
Mason Carrico
Price Target
$70
2025-07-09
initiated
Overweight
Reason
Stephens analyst Mason Carrico initiated coverage of Procept BioRobotics with an Overweight rating and $70 price target. The firm expects the company to post "robust" growth and margin expansion as adoption of Aquablation continues to expand. Aquablation is disrupting the benign prostatic hyperplasiamarket by taking share from existing procedures and capturing patients who historically delayed or avoided surgery, the analyst tells investors in a research note. Stephens believes expanding into prostate cancer has the potential to drive meaningful growth for Procept longer-term.
Oppenheimer
Oppenheimer
Perform
initiated
$323M
2025-07-07
Reason
Oppenheimer
Oppenheimer
Price Target
$323M
2025-07-07
initiated
Perform
Reason
Oppenheimer initiated coverage of Procept BioRobotics with a Perform rating. Procept has pioneered the Aquablation image-guided high-pressure, non-thermal waterjet ablation system for benign prostatic hyperplasia treatment. The firm notes that Aquablation's clinical value proposition has been robustly demonstrated in multiple clinical trials, with an impressive 4-year revenue CAGR of about 75%. FY25 guidance at $323M seems conservative, and a Q2 beat is expected, Oppenheimer adds. The firm's rating reflects its assessment of risk reward at these levels. Oppenheimer is constructive on the science but needs to get comfortable with utilization in a fragmented market and the risks with a potential 20% cut to physician payment rates.
BofA
Craig Bijou
Buy
downgrade
$104 -> $84
2025-04-25
Reason
BofA
Craig Bijou
Price Target
$104 -> $84
2025-04-25
downgrade
Buy
Reason
BofA analyst Craig Bijou lowered the firm's price target on Procept BioRobotics to $84 from $104 and keeps a Buy rating on the shares. Despite a "solid beat and raise," shares were down 6% as the company's inline system sales seem to have raised questions on future momentum, the analyst tells investors. However, the firm thinks the handpiece rebound and the improving utilization are better indicators, adds the analyst, who lowered the firm's target as peer multiples have fallen and also for an updated model following the Q1 results.
Morgan Stanley
Patrick Wood
Overweight
downgrade
$95 -> $71
2025-04-24
Reason
Morgan Stanley
Patrick Wood
Price Target
$95 -> $71
2025-04-24
downgrade
Overweight
Reason
Morgan Stanley analyst Patrick Wood lowered the firm's price target on Procept BioRobotics to $71 from $95 and keeps an Overweight rating on the shares. Despite a "solid first quarter print" and positive intra-quarter commentary, the stock has traded down significantly, which is "probably not deserved," the analyst tells investors. After speaking with management, the firm is "incrementally constructive" on elevated utilization trends continuing into the Q2 and thinks the pullback presents a buying opportunity, the analyst added.
Truist Securities
Richard Newitter
Strong Buy
Maintains
$90 → $70
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$90 → $70
2025-04-11
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Procept BioRobotics to $70 from $90 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Procept Biorobotics Corp (PRCT.O) is -44.42, compared to its 5-year average forward P/E of -27.26. For a more detailed relative valuation and DCF analysis to assess Procept Biorobotics Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.26
Current PE
-44.42
Overvalued PE
-12.71
Undervalued PE
-41.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-45.14
Current EV/EBITDA
-131.57
Overvalued EV/EBITDA
-7.48
Undervalued EV/EBITDA
-82.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
15.32
Current PS
9.43
Overvalued PS
22.89
Undervalued PS
7.75

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 425.35% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 465.92% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 425.35% over the last month.
Sold
Bought

PRCT News & Events

Events Timeline

(ET)
2025-07-16
09:04:48
Leerink sees positive readthrough for Procept after CMS' OPPS proposed rule
select
2025-07-14 (ET)
2025-07-14
21:39:00
Procept BioRobotics says Aquablation therapy assigned a Category I code
select
2025-04-24 (ET)
2025-04-24
07:08:05
Procept BioRobotics sees FY25 revenue $323M, consensus $321.67M
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-16TipRanks
3 Best Stocks to Buy Now, 7/16/2025, According to Top Analysts

  • Top Stock Picks: Analysts recommend three stocks as Strong Buys: PROCEPT BioRobotics (PRCT) with a 43.65% upside, Permian Resources (PR) with a 31% upside, and Primo Brands (PRMB) with a 47% upside, all receiving recent Buy ratings from top analysts.

  • Analyst Ranking: TipRanks ranks financial analysts based on their rating success and profitability, highlighting the accuracy of Top Analysts who have earned five-star rankings.

Preview
9.0
07-15NASDAQ.COM
PROCEPT BioRobotics Announces Category I CPT Code Assignment for Aquablation Therapy Effective January 1, 2026

  • Aquablation Therapy CPT Code Announcement: PROCEPT BioRobotics has received a Category I CPT code for its Aquablation therapy, effective January 1, 2026, which is expected to enhance access and adoption of this robotic-assisted treatment for benign prostatic hyperplasia (BPH).

  • Medicare Payment Details: The proposed Medicare payment for Aquablation therapy in 2026 is approximately $540, slightly higher than traditional TURP procedures, reflecting the therapy's clinical value and potential as a standard surgical option for BPH.

Preview
7.0
07-15Newsfilter
Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

  • Aquablation Therapy Code Assignment: PROCEPT BioRobotics announced that Aquablation therapy has been assigned a Category I CPT code effective January 1, 2026, which will replace the previous Category III code, enhancing its recognition and adoption in urology practices.

  • Medicare Payment Rates: The proposed Medicare Physician Fee Schedule for 2026 includes a payment rate of approximately $540 for Aquablation therapy, slightly higher than the $529 for TURP, reflecting its clinical value and potential to improve patient access to treatment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Procept Biorobotics Corp (PRCT) stock price today?

The current price of PRCT is 58.35 USD — it has decreased -0.98 % in the last trading day.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s business?

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.

arrow icon

What is the price predicton of PRCT Stock?

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 78.50 USD with a low forecast of 70.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s revenue for the last quarter?

Procept Biorobotics Corp revenue for the last quarter amounts to 69.16M USD, increased 55.28 % YoY.

arrow icon

What is Procept Biorobotics Corp (PRCT)'s earnings per share (EPS) for the last quarter?

Procept Biorobotics Corp. EPS for the last quarter amounts to -0.45 USD, decreased -11.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for Procept Biorobotics Corp (PRCT)'s fundamentals?

The market is revising Upward the revenue expectations for PROCEPT BioRobotics Corporation (PRCT) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 9.21%.
arrow icon

How many employees does Procept Biorobotics Corp (PRCT). have?

Procept Biorobotics Corp (PRCT) has 756 emplpoyees as of July 19 2025.

arrow icon

What is Procept Biorobotics Corp (PRCT) market cap?

Today PRCT has the market capitalization of 3.23B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free